Top 5 Undervalued Stocks To Invest In 2019

Innovation can still produce results even in a sluggish U.S. spine market, as seen with the ongoing growth at companies like K2M (KTWO) and Globus (GMED). In the case of K2M, the story is still about the company’s disruptive product development in degenerative and complex spine, supported by a strong platform in 3D-printed implants. With that, the shares have done okay since my last update – rising close to 10%, which is not as good as Globus, but pretty good next to other med-techs in the spine space like Stryker (SYK) and NuVasive (NUVA).

I continue to believe that K2M shares are undervalued. The company’s liquidity and cash flow situation is not ideal, but spending money on product development and competitive rep hires to support those product launches makes sense, and I believe the company will get to double-digit FCF margins within five years. With that, I’d consider buying into the mid-$20s.

Ongoing Product-Led Share Growth

Although the past few quarters have not been strong for the U.S. spine market as a whole, K2M is outgrowing the market on the back of share-taking new products/platforms like Yukon OCT (complex), Everest MI (MIS, degenerative) and Cascadia 3D (MIS, degenerative). Revenue rose 8% in the first quarter after rising 9% in the fourth quarter, with good growth in complex in both periods. While MIS slowed a bit in the first quarter (to around 6% yoy growth), the year-ago comp was difficult. Degenerative actually accelerated from the fourth quarter, with 9% yoy growth.

Top 5 Undervalued Stocks To Invest In 2019: Seacoast Banking Corporation of Florida(SBCF)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Seacoast Banking Co. of Florida (SBCF)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Great Western Bancorp (NYSE: GWB) and Seacoast Banking Co. of Florida (NASDAQ:SBCF) are both finance companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability.

  • [By Joseph Griffin]

    Here are some of the news articles that may have impacted Accern Sentiment’s analysis:

    Get Seacoast Banking Co. of Florida alerts:

    Seacoast Banking Co. of Florida (SBCF) EVP Sells $43,249.63 in Stock (americanbankingnews.com) Q2 2018 EPS Estimates for Seacoast Banking Co. of Florida Cut by FIG Partners (SBCF) (americanbankingnews.com) Q2 2018 EPS Estimates for Seacoast Banking Co. of Florida (SBCF) Cut by Analyst (americanbankingnews.com) Zacks Investment Research Lowers Seacoast Banking Co. of Florida (SBCF) to Sell (americanbankingnews.com)

    SBCF has been the subject of several recent research reports. Zacks Investment Research upgraded Seacoast Banking Co. of Florida from a “sell” rating to a “hold” rating in a research report on Wednesday, March 28th. ValuEngine raised shares of Seacoast Banking Co. of Florida from a “hold” rating to a “buy” rating in a research note on Saturday, April 21st. BidaskClub raised shares of Seacoast Banking Co. of Florida from a “sell” rating to a “hold” rating in a research note on Saturday, February 10th. Guggenheim reissued a “hold” rating and issued a $28.00 price objective on shares of Seacoast Banking Co. of Florida in a research note on Wednesday, January 31st. Finally, Hovde Group raised shares of Seacoast Banking Co. of Florida from a “market perform” rating to an “outperform” rating and decreased their price objective for the stock from $30.00 to $29.00 in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $29.00.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Seacoast Banking Co. of Florida (SBCF)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Undervalued Stocks To Invest In 2019: Boeing Company (BA)

Advisors’ Opinion:

  • [By Paul Ausick]

    Following a one-week absence, The Boeing Co. (NYSE: BA) has returned as the top-performing stock among the Dow 30 last week. Unlike its performance in 2017 when it grabbed the top ranking early and held it for most of the year, Boeing has bounced into and out of the top spot this year. The company’s shares added about 3.6% in what was a good week for the index itself. For the year to date, Boeing shares have gained 25.3%.

  • [By Paul Ausick]

    Boeing Co. (NYSE: BA) stock regained some ground last week after dropping about 3.4% in the prior week. Shares added 2.86% last week, but that was less than the Dow Jones industrial average’s gain of nearly 3.5%. The stock remains the Dow’s best performer for the year to date, however, with a gain of 20.2%.

  • [By Jon C. Ogg]

    The Boeing Company (NYSE: BA) was down 2.25 at $321.80 on Tuesday, but that is down 13% from the all-time high of $371.60. If tariffs are bringing trade wars, maybe a lot of those new plane orders are at risk.

  • [By ]

    And with softening talk on trade stemming from Washington, even Boeing (BA) and Caterpillar (CAT) were able to end the day higher.

    Cramer and the AAP team are talking about Broadcom’s (AVGO) huge $12 billion share-repurchase program. The timing is extraordinary. Find out what they’re telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

  • [By Garrett Baldwin]

    President Trump’s administration is preparing to slap China with 10% tariffs on roughly $200 billion in goods. The news sent stocks in Asia and Europe tumbling. The new list of goods includes everything from vegetables to baseballs. China’s Commerce Ministry said that the new measures were “unacceptable” and suggested that the country will need to respond with “necessary countermeasures.” In deal news,Twenty-First Century Fox Inc.(NYSE: FOXA) announced that it will purchase Sky Plc. (OTC MKTS: SKYAY) in a deal worth $32.5 billion. The Murdoch-run firm had been in a bidding war with U.S. rival Comcast Corp.(Nasdaq: CMCSA). Earnings season will continue to build momentum this week. Markets are very interested in the reports coming tomorrow and Friday. JPMorgan Chase & Co. (NYSE: JPM), Citigroup Inc. (NYSE: C), and Wells Fargo & Co.(NYSE: WFC) will all report earnings on Friday. According to FactSet, corporate earnings are expected to have increased by 20% during the second quarter.
    Four Stocks to Watch Today: CAT, BA, PFE, FB
    Shares of Caterpillar Inc. (NYSE: CAT) and Boeing Co. (NYSE: BA) are both off more than 1% this morning as markets fear the ongoing trade spat between the United States and China. Investors are concerned that the tariffs will both increase the cost of raw materials and impact profitability across the board. Pfizer Inc. (NYSE: PFE) is making headlines on news that it will not be raising prices thanks to increased pressure from the Trump administration. The pharmaceutical giant’s CEO had reportedly discussed drug prices with President Trump and the head of Health and Human Services. “Pfizer is rolling back price hikes, so American patients don’t pay more. We applaud Pfizer for this decision and hope other companies do the same,” President Trump tweeted. Facebook Inc. (Nasdaq: FB) is taking a hit this morning thanks to a big fine from the British government. Regulators in the United Kingdom said they have fined the firm a

  • [By ]

    Jim Cramer, founder of TheStreet, talked with Bob Lang, founder of Explosive Options, about three selloff stocks that he believes are worth holding onto. Cramer and Lang examined whether the selloffs in Caterpillar (CAT) , Boeing (BA)  and United Technologies (UTX)  represent genuine buying opportunities. Lang told Cramer the selling in these three former market darlings was premature because the numbers look good and the technicals look even better.

Top 5 Undervalued Stocks To Invest In 2019: Proteon Therapeutics, Inc.(PRTO)

Advisors’ Opinion:

  • [By Max Byerly]

    Proteon Therapeutics (NASDAQ: PRTO) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Top 5 Undervalued Stocks To Invest In 2019: Corcept Therapeutics Incorporated(CORT)

Advisors’ Opinion:

  • [By Max Byerly]

    AJ Wealth Strategies LLC raised its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 113.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 441,103 shares of the biotechnology company’s stock after acquiring an additional 234,483 shares during the quarter. Corcept Therapeutics comprises approximately 1.4% of AJ Wealth Strategies LLC’s portfolio, making the stock its 14th biggest holding. AJ Wealth Strategies LLC owned approximately 0.38% of Corcept Therapeutics worth $6,934,000 as of its most recent SEC filing.

  • [By Lisa Levin] Gainers
    McDermott International, Inc. (NYSE: MDR) rose 19 percent to $7.20 in pre-market trading. Subsea 7 S.A. confirmed a $7.00 per share proposal to acquire McDermott.
    Clarus Corporation (NASDAQ: CLAR) rose 18.5 percent to $8.00 in pre-market trading.
    Enbridge Inc. (NYSE: ENB) rose 9.3 percent to $34.09 in pre-market trading after falling 2.41 percent on Friday.
    Lannett Company, Inc. (NYSE: LCI) rose 8.4 percent to $18 in pre-market trading. Lannett named Maureen M. Cavanaugh as senior vice president and chief commercial operations officer.
    Navios Maritime Midstream Partners L.P. (NYSE: NAP) rose 7.1 percent to $4.55 in pre-market trading after gaining 11.26 percent on Friday.
    Corcept Therapeutics Incorporated (NASDAQ: CORT) rose 6.9 percent to $18.80 in pre-market trading after falling 3.19 percent on Friday.
    Helios and Matheson Analytics Inc. (NASDAQ: HMNY) rose 5.7 percent to $2.40 in pre-market trading after falling 10.98 percent on Friday.
    Vectren Corporation (NYSE: VVC) shares rose 5.6 percent to $69.20 in pre-market trading. CenterPoint Energy, Inc. (NYSE: CNP) announced plans to acquire Vectren for $72 per share in cash
    Genprex, Inc. (NASDAQ: GNPX) shares rose 5.2 percent to $4.50 in pre-market trading.
    Atossa Genetics Inc. (NASDAQ: ATOS) rose 5.1 percent to $3.70 in pre-market trading after declining 19.35 percent on Friday.
    Sangamo Therapeutics, Inc. (NASDAQ: SGMO) shares rose 5 percent to $20 in pre-market trading.
    Magellan Midstream Partners, L.P. (NYSE: MMP) shares rose 5 percent to $68.41 in pre-market trading.
    Halozyme Therapeutics, Inc. (NASDAQ: HALO) shares rose 4.9 percent to $19.78 in the pre-market trading session.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Ethan Ryder]

    ValuEngine lowered shares of Corcept Therapeutics (NASDAQ:CORT) from a buy rating to a hold rating in a research note issued to investors on Friday.

  • [By Logan Wallace]

    Sei Investments Co. lessened its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 27.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,279 shares of the biotechnology company’s stock after selling 5,271 shares during the quarter. Sei Investments Co.’s holdings in Corcept Therapeutics were worth $235,000 at the end of the most recent reporting period.

Top 5 Undervalued Stocks To Invest In 2019: InterXion Holding N.V.(INXN)

Advisors’ Opinion:

  • [By Shane Hupp]

    Interxion (NYSE:INXN) was the target of unusually large options trading on Tuesday. Traders acquired 960 call options on the company. This is an increase of 1,584% compared to the typical daily volume of 57 call options.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on InterXion (INXN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Jacobson & Schmitt Advisors LLC lessened its holdings in shares of Interxion (NYSE:INXN) by 1.8% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 102,697 shares of the technology company’s stock after selling 1,927 shares during the quarter. Interxion comprises approximately 4.4% of Jacobson & Schmitt Advisors LLC’s portfolio, making the stock its 5th biggest holding. Jacobson & Schmitt Advisors LLC owned 0.14% of Interxion worth $6,378,000 at the end of the most recent quarter.

  • [By Stephan Byrd]

    Interxion (NYSE:INXN) had its price objective boosted by Citigroup from $68.00 to $75.00 in a research note issued to investors on Friday morning. Citigroup currently has a buy rating on the technology company’s stock.

Leave a Reply

Your email address will not be published. Required fields are marked *